Government Approves New Cancer Drug Reimbursement Rules

Photo courtesy of Bangkok Post

The government has enacted new reimbursement guidelines permitting patients with advanced non-small cell lung cancer (NSCLC) to utilize targeted therapies, Erlotinib or Gefitinib, as initial treatment options. This policy change, effective December 1, will relieve patients of the financial burden for these high-cost medications. The update primarily impacts individuals with stage IV lung cancer possessing EGFR mutations, which are prevalent among Thai patients.

The adjustments were announced by Deputy Government Spokeswoman Airin Phanrit, who confirmed that the Comptroller General's Department had refined its guidelines to include coverage for these expensive cancer and haematology drugs. The shift aims to bypass the traditional chemotherapy-first approach, granting immediate access to these therapies that have shown the potential to inhibit tumour growth for 9–12 months. Medical professionals will supervise patients closely during this early treatment period under the revised reimbursement scheme.

Erlotinib emerges as the favored option, though Gefitinib can be substituted if patients exhibit adverse reactions to the former. Both medications are integrated into the National Essential Medicines List, ensuring they are accessible across various healthcare coverage plans, including Universal Health Coverage, Social Security, and Civil Servant Medical Benefits, at no additional cost to patients. The reimbursement aligns with monthly usage for the initial three months and switches to a quarterly basis.

EGFR mutations are detected in approximately 50% of patients in Thailand are diagnosed with adenocarcinoma-type lung cancer. Without these targeted treatments, the survival rate for stage IV patients is typically limited to about three months. However, employing Erlotinib or Gefitinib can extend disease control to a period of 9–12 months. Patients may then transition to chemotherapy or other alternative targeted therapies to further extend survival, reported Bangkok Post.

Key Takeaways:

• New guidelines allow NSCLC patients with EGFR mutations to access targeted therapies without first undergoing chemotherapy.
• Erlotinib and Gefitinib, covered under all national health schemes, are expected to prolong tumour control for up to 12 months.
• The policy could notably extend the survival duration for stage IV lung cancer patients in Thailand.

Related Stories

Everything you need to know about blood cancer treatment in Bangkok

Discover the fruits found in Thailand that help combat cancer

  Adapted by ASEAN Now from Bangkok Post 2025-12-04